The system was purchased by a global pharmaceutical company and will become one of the key components in its gene expression and protein biochemistry department
NextGen Sciences has announced the first sale of an Expressionfactory in the UK.
The system was purchased by the global pharmaceutical company, GlaxoSmithKline, and will become one of the key components in the company's gene expression and protein biochemistry department.
The Expressionfactory fully automates protein expression on a single platform from 'gene-to-protein'.
Beginning with a gene, gene fragment or domain, the advanced system expresses each gene in parallel in a variety of vectors.
Uniquely, the Expressionfactory also grows each of the newly created cell lines in parallel, before purifying all of the different versions of each protein.
This is achieved automatically, without user supervision or intervention. The Expressionfactory allows a matrix approach for the cloning and expression of any gene, increasing the chances of successfully isolating useful protein in amounts sufficient for research.
"The Expressionfactory has been four years in development, and we are delighted that GSK has purchased the first system in the UK.
"Our objective is to provide integrated solutions to automate and improve protein research, and we are proud of the unique capabilities of the Expressionfactory" commented Grant Cameron, commercial director, NextGen Sciences.
